Chart pattern: Inverse Head and Shoulders (weekly)
▲ Broken out
Broke on Oct 16, 2026 · measured target $361.49 (+18%). Details →
Oct 21, 7:13 AM ET
CME Group reported third-quarter 2026 results on October 21, 2026, with revenue of $1.7 billion, up from $1.5 billion a year earlier, and diluted earnings per share of $2.89, up from $2.49. Adjusted diluted EPS was $3.02 versus $2.68 a year earlier, and the company returned nearly $1 billion to shareholders during the quarter.
- Q3 2026 total revenues of $1,737.3 million versus $1,537.6 million in Q3 2025
- Diluted EPS of $2.89 versus $2.49; adjusted diluted EPS of $3.02 versus $2.68
- Average daily volume of 29.4 million contracts, a third-quarter record
- Returned nearly $1 billion to shareholders: $465 million in dividends and $524 million in share repurchases
Read the filing on SEC.gov ↗
Sep 9, 11:15 AM ET
CME Group announced senior leadership changes in its finance and legal divisions. Jack Tobin becomes Deputy Chief Financial Officer on November 2, 2026, and Chief Financial Officer in March 2027, when Lynne Fitzpatrick becomes Chief Executive Officer. The changes also bring a new General Counsel, John Marchese, and a new Chief Accounting Officer, Matthew Render, but the filing gives no financial results or figures tied to these appointments.
- Jack Tobin becomes Deputy Chief Financial Officer on November 2, 2026, and Chief Financial Officer in March 2027, when Lynne Fitzpatrick becomes Chief Executive Officer.
- Matthew Render succeeds Tobin as Managing Director, Chief Accounting Officer effective November 2, 2026, after joining CME Group in August 2026.
- John Marchese is promoted to General Counsel, succeeding Jonathan Marcus, who has served as General Counsel since 2022 and is stepping down later this month.
- Tobin previously planned to retire effective October 30, 2026, but will now continue with the company.
Read the filing on SEC.gov ↗
Jul 22, 7:15 AM ET
CME Group reported second-quarter 2026 results for the quarter ended June 30, 2026. Total revenue rose to $1.7 billion from $1.69 billion a year earlier, and diluted earnings per share were $2.88 versus $2.81, but GAAP operating income fell to $1.1 billion from $1.13 billion.
- Total revenue was $1,706.2 million, up from $1,692.0 million in Q2 2025; clearing and transaction fees were $1,352.5 million.
- Diluted EPS was $2.88 versus $2.81; adjusted diluted EPS was $2.99 versus $2.96.
- Operating income was $1,107.1 million versus $1,129.3 million; adjusted operating income was $1,185.0 million versus $1,200.8 million.
- As of June 30, 2026, cash was $2.3 billion and debt was $3.4 billion; the company repurchased $695 million of its common shares and paid about $468 million in dividends in the quarter.
Read the filing on SEC.gov ↗
Jun 17, 8:35 AM ET
CME Group said Chairman and CEO Terry Duffy will become Executive Chairman, and President and CFO Lynne Fitzpatrick will succeed him as CEO. The change takes effect on the later of March 1, 2027 and the date the company files its 2026 Form 10-K. The company will also search for a new CFO to succeed Fitzpatrick.
- Transition effective on the later of March 1, 2027 and the filing date of the 2026 Form 10-K; Board approved it June 16, 2026
- Duffy serves as Executive Chairman from the Transition Date through December 31, 2027
- Fitzpatrick's agreement sets a $1.2 million annual base salary, a bonus opportunity of 200% of salary and a long-term incentive opportunity of 700% of salary
- Fitzpatrick's severance includes a lump sum of two times annual base salary and 18 months of Company-paid healthcare coverage
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.